Arbutus Biopharma/$ABUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arbutus Biopharma
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Ticker
$ABUS
Sector
Primary listing
Employees
19
Headquarters
Website
ABUS Metrics
BasicAdvanced
$827m
-
-$0.17
0.74
-
Price and volume
Market cap
$827m
Beta
0.74
52-week high
$5.10
52-week low
$2.94
Average daily volume
2.2m
Financial strength
Current ratio
15.727
Quick ratio
15.521
Long term debt to equity
4.755
Total debt to equity
5.469
Interest coverage (TTM)
-278.88%
Profitability
EBITDA (TTM)
-26.688
Gross margin (TTM)
-79.23%
Net profit margin (TTM)
-237.88%
Operating margin (TTM)
-192.08%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
-14.94%
Return on equity (TTM)
-38.52%
Valuation
Price to revenue (TTM)
57.141
Price to book
10.56
Price to tangible book (TTM)
10.56
Price to free cash flow (TTM)
-20.302
Free cash flow yield (TTM)
-4.93%
Free cash flow per share (TTM)
-0.207
Growth
Revenue change (TTM)
128.21%
Earnings per share change (TTM)
-53.58%
3-year revenue growth (CAGR)
-28.80%
10-year revenue growth (CAGR)
-4.90%
3-year earnings per share growth (CAGR)
-27.57%
10-year earnings per share growth (CAGR)
-18.66%
ABUS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arbutus Biopharma stock?
Arbutus Biopharma (ABUS) has a market cap of $827M as of May 02, 2026.
What is the P/E ratio for Arbutus Biopharma stock?
The price to earnings (P/E) ratio for Arbutus Biopharma (ABUS) stock is 0 as of May 02, 2026.
Does Arbutus Biopharma stock pay dividends?
No, Arbutus Biopharma (ABUS) stock does not pay dividends to its shareholders as of May 02, 2026.
When is the next Arbutus Biopharma dividend payment date?
Arbutus Biopharma (ABUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arbutus Biopharma?
Arbutus Biopharma (ABUS) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.